myotonia Archives | Be Korea-savvy

Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

Zug, Switzerland, Jan. 8 (Korea Bizwire) - Lupin is pleased to announce that the European Commission (EC) has approved NaMuscla® (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. Non-dystrophic myotonic disorders are a group of rare, inherited neuromuscular disorders which cause the inability to relax muscles following voluntary contraction. NaMuscla® [...]

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

ZUG, Switzerland, Oct. 19 (Korea Bizwire) - Lupin Neurosciences, a specialty pharma division of Lupin Ltd, today announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of NaMuscla™ (mexiletine hydrochloride) for the symptomatic treatment of myotonia [...]